Related Experiment Video
Updated: May 22, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
A Non-Invasive Approach to Pulmonary Hypertension
Dalma Horvat1, Rares Ilie Orzan1, Lucia Agoston-Coldea1,2
12nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 2-4 Clinicilor, 400006 Cluj-Napoca, Romania.
Abstract:
Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disease associated with a poor prognosis, with progressive right ventricular (RV) failure being the main cause of death in this vulnerable population. Right heart catheterization remains the gold standard for assessing pulmonary hemodynamics. However, due to its invasive nature, non-invasive imaging methods are gaining increasing interest. Two-dimensional transthoracic echocardiography serves as the primary screening tool for PH and is widely used to estimate its likelihood. Nevertheless, this technique has several limitations, partially addressed through the assistance of a three-dimensional echocardiography. Cardiac magnetic resonance imaging (CMR) provides a comprehensive evaluation of both the morphology and hemodynamics of right ventricle-pulmonary artery unit, offering essential information for diagnosis, prognosis, and therapeutic monitoring. While two-dimensional cardiac CMR enables non-invasive characterization of pulmonary hemodynamics, advances in 4D-flow cardiac CMR allow for a more detailed analysis. These advancements enable the assessment of flow patterns, energetics, wall shear stress and severity, offering a more nuanced understanding of the disease. This review aims to provide an in-depth summary of the current data on advanced non-invasive imaging techniques for PH.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

